Chronic kidney disease (CKD) is a relatively recently recognised condition. People with CKD are much more likely to suffer from cardiovascular events than progress to established renal failure. Controlling systolic blood pressure should slow the progression of disease and reduce mortality and morbidity. However, no systematic review has been conducted to explore the effectiveness of quality-improvement interventions to lower blood pressure in people with CKD.
INTRODUCTION
Chronic kidney disease (CKD) is a new priority for primary care, and cross-sectional studies show that there is a gap between evidence and practice. 1 At present, many people are not managed according to current guidance. 2 People with CKD are at greater risk of cardiovascular morbidity and mortality, which are approximately equal to and additive to the excess rates seen in diabetes. 3 Only a small minority of people with CKD progress to dialysis dependence. The 2008 UK Renal Registry report indicates a prevalent dialysis population of 0.07%. 4 Data from East Kent indicate that over 80% of people with CKD have a disease that is stable over time. 5 It has been estimated that the cost of implementation of national guidance could be recouped by delaying the dialysis of one patient per practice of 10 000 patients for a single year. 6 CKD is common, affecting 5-10% of the population. 7, 8 It can be diagnosed from a blood test, much of its management can be carried out in primary care, and general practice computer records provide reliable access to data about the quality of management of this condition. 9 CKD for the purposes of this review is defined as an estimated glomerular filtration rate (eGFR) of <60 ml/min/1.73m 2 (that is, stage 3 to 5 CKD). eGFR is derived from four pieces of data: age, sex, serum creatinine, and, where appropriate, corrected for ethnicity. 10, 11 CKD is strongly associated with cardiovascular risk and cardiovascular comorbidities including diabetes. 12 Progression of CKD may lead to established renal failure requiring renal dialysis or transplantation; people with significant proteinuria are particularly at risk. The mainstay of primary care management is strict control of systolic blood pressure, especially in people with diabetes or proteinuria, and management of cardiovascular risk. 1 More aggressive management of blood pressure in CKD, especially in people with proteinuria, slows the progression of CKD. 13 In the UK, national guidance has set out management goals, 14, 15 supported by a financially incentivised chronic disease-management programme in primary care, the Quality and Outcomes Framework (QOF). 16 These initiatives have raised awareness of the condition; however, a significant gap exists in the quality of primary care management, including the suboptimal control of blood pressure. 17, 18 Two recent systematic reviews of qualityimprovement (QI) strategies in hypertension have been published. Walsh et al included a wide range of study designs and QI interventions to lower blood pressure; 19 before and after recording of blood pressure was a precondition for inclusion in their analysis. Of 3000 citations, 44 articles underwent quantitative analysis. A median reduction in systolic blood pressure of 4.5 mmHg was found in intervention groups. QI interventions involving team or organisational change may have the largest effect, although as many of the interventions were complex it was often hard to discern which component was of greatest importance. Fahey et al restricted their analysis to randomised controlled trials (RCTs) in primary care or other community or office settings; 20 7000 relevant citations were identified, and 56 trials included in their meta-analysis. The findings were dominated by the large Hypertension Detection and Follow-up (HDFP) programme, which showed a large reduction in systolic blood pressure of 11.7 mmHg, 21, 22 but none of the other included studies were associated with large clinically important reductions. However, neither of these reviews included any subgroup analysis in CKD patients, a population in whom blood pressure control is widely recognised to be challenging and frequently requires the use of multiple antihypertensive agents.
Prior to embarking on a programme of research to explore how to improve the quality of primary care management of CKD, 23 a systematic review was carried out to assess the efficacy of QI strategies to lower systolic blood pressure in people with CKD, using systolic blood pressure reduction as a surrogate for reducing cardiovascular risk and slowing the progression of renal disease.
METHOD

Objectives
The study objective was to identify the effect of QI interventions upon the primary outcome measures, reduction in systolic blood pressure, or delay or reduction in the onset of established renal failure. Secondary outcome measures included: diastolic blood pressure; change in diastolic blood pressure; percentage of patients achieving systolic or diastolic blood pressure within a target range; and any recording of accelerated decline in eGFR or change in albuminuria or proteinuria. The QI interventions were grouped into: educational interventions; interventions providing audit and comparative feedback; and organisational or team change.
An additional aim was to explore, through subgroup analysis, the influence of the interventions on people with milder (stage 3) or more severe (stage 4 and 5) CKD; the setting of care (outpatients, shared care, community or primary care); the management of patients with and without proteinuria; and the management of comorbidities, especially diabetes.
Literature search
An appropriate search strategy was developed, in collaboration with the Cochrane Effective Practice and Organisation of Care Group (EPOC) in Canada, 24 and the Cochrane Renal Group in Australia. 25 These groups also ran the searches for the study on their own databases, which have both been developed to identify literature from key bibliographic databases. Their databases are complementary: EPOC identifies reviews of interventions designed to improve practice and clinical effectiveness; the Cochrane Renal Group identifies RCTs and other controlled clinical trials (CCTs). These were returned in March 2008, the date of the last search. The search terms used were: (hypertens* or antihypertens* or blood pressure or
How this fits in
The management of CKD is increasingly a responsibility of primary care. Achieving blood pressure control is important to reduce the risks of cardiovascular disease and end-stage renal disease, but is frequently challenging. A small number of comparative quality improvement studies suggest that significant reductions in blood pressure can be achieved through non-doctor led educational and therapeutic interventions. systolic BP or CVD or cardiovascular) and (kidney* or renal or nephrol* or CKD or glomerular filtration rate or GFR or eGFR or creatinine). Both Cochrane groups run ongoing searches to identify any trials of QI interventions relevant to primary care and/or renal disease, respectively.
Inclusion and exclusion criteria
Only studies that had a control or comparator arm were included. The comparator arm might be 'usual practice' or a small-scale intervention such as 'guidelines and prompts'. Acceptable designs included: RCT and cluster RCT; other CCT including studies containing at least two cohorts assembled prospectively using an arbitrary but non-random allocation procedure; and before and after studies (with a contemporaneous observation for cohorts differing in exposure to the QI intervention[s]).
Included subjects were adults with hypertension treated and stage 3 to 5 CKD (equivalent to an eGFR <60ml/min/1.73m 2 ) managed in an ambulatory care setting: primary care or community setting, shared care, or hospital outpatients. As a substantial proportion of people with diabetes have CKD, diabetes was used as a proxy for CKD where impaired renal function was reported. A previous study of routinely collected data reported that at least 31% of people with diabetes have CKD. 12 Studies not meeting the above criteria were excluded; additionally, articles published before 1990; those not on human subjects; and those not in English were not included. Studies of dialysis patients were also excluded. The cut-off of 1990 was selected because there was no guidance on CKD management or evidence base for interventions prior to this time. 26 There was also concern about the use of angiotensin-converting enzyme inhibitors (which were not the mainstay of management) revealing renal artery stenosis and precipitating renal failure. 27 Creatinine assays were non-standardised at that time, making comparisons more difficult.
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Study assessment
Titles and abstracts were screened by two independent observers to determine relevance. Disagreements were resolved by consensus. Relevant full abstracts and full texts were screened by two independent observers. Using a structured collection form, data were extracted on: study population; interventions; study design; outcomes; and potential sources of bias.
The studies were assessed in four steps: (1) reviewing the abstracts to identify relevant full papers; (2) extracting data about the quality and characteristics of the studies (type of study, subjects and setting, process of randomisation or type of comparator group, outcome measure); (3) extracting the results (size of study population, outcome measures [blood pressure or progression to established renal failure, change in eGFR, subgroups identified]); and (4) combining results taking into account clinical homogeneity (that is, similarity of populations and settings). A meta-analysis of the results was conducted where appropriate. Where this was not possible, but studies contain relevant information, a narrative review is provided.
Statistical analysis
Results from randomised controlled trials, quasirandomised trials, and before and after studies were combined. For change in blood pressure, a weighted mean difference with a random effects model and 95% confidence interval (CI) was used. Absolute measurements of blood pressure were combined with change measurements if no change measurements could be obtained from the authors of the papers. Dichotomous outcomes (progression to established renal failure, or number or patients achieving target blood pressure) were combined using odds ratios and the Mantel-Haenszel method with random effects. Heterogeneity was measured using the Higgins I2 method, and investigated using the prespecified subgroups.
Sensitivity analysis
Study quality was used as a criterion for sensitivity analysis. The study planned to compare the outputs of the studies that met the highest quality criteriaRCTs -with those studies with lower quality criteria scores, using statistical tests for interaction. The results of using fixed and random effects models were compared, and the study aimed to use funnel plots to look for publication bias.
RESULTS
Initial review of the search results
The searches identified 69 studies: 26 from EPOC and 43 from the renal group. The authors independently agreed that, from the abstract, 35 did not fit the inclusion criteria, and then jointly agreed to reject another four studies, leaving 30 studies for which full papers were requested. The main reasons for rejection were: non-relevant patient group (patients with established renal failure treated by dialysis, or patients with urinary or catheter infection; lack of comparator group; or studies focused on another specific area (for example, stroke or renal anaemia). An overview of the process of selection of the core articles is shown in Figure 1 .
Review of the full papers
The study then set out to obtain full versions of the 30 selected papers. A spreadsheet was used to independently assess each paper, recording subject and settings, whether randomised, the comparator group, and the outcome measures. The findings were then reviewed. It was not possible to obtain copies of six of these papers from the British Library; 12 papers were identified for final inclusion. The main reasons for exclusion were: pre-1990 study not relevant to current practice (n = 4); no comparator group (n = 3); not a QI intervention (n = 3); study based mostly on dialysis patients (n = 2); and no blood pressure data (n = 2). Two other papers were rejected: one lacked blood pressure data, and the other because of pre-1990 study overlap. For one of the papers, the authors were approached, unsuccessfully, to provide before and after blood pressure and serum creatinine data. 29 
Detailed extraction of the results
Of the final 12 studies, four could be included in a quantitative comparative analysis of their effect on systolic blood pressure; three were randomised studies and one was an observational study with usual practice group as a comparator (Figure 2 ). Narrative findings are reported from five other studies, and a further two were excluded which, on closer examination, were deemed not to be QI interventions. 30, 31 Finally, another study was excluded because it was the 3-year follow-up of a study, 32 superseded by a 5-year follow-up, which was included. 33 Three sets of quantitative results from three RCTs were brought together. All were well-designed studies showing the effects of nurse-or pharmacistled interventions, though with very specific and different patient groups ( Table 1 ). The first is a randomised study of renal transplant patients who were living in the community. 34 The second study showed the effectiveness of a nurse-led intervention in the management of black men with hypertension. 33 The third RCT was a Canadian study of a nurse intervention in First Nations people; although a study 
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of patients with hypertension and diabetes, the quoted albumin/creatinine ratios implies that many had CKD. 35 The mean albumin/creatinine ratio was >3.5 mg/mmol in women is indicative of renal damage and is therefore diagnostic of CKD. 15 These studies suggest that these QI interventions lower systolic blood pressure by a mean of 10.6 mmHg (95% confidence interval [CI] = -15.8 to -5.3), and that this effect is statistically significant (P<0.0001, Figure 2 ). Results were very similar with the use of a random effects model (mean difference -10.90 mmHg; 95% CI = -17.72 to -4.08).
The study also included quantitative results from an observational non-randomised study from the Netherlands, as it was felt that the improved blood pressure control achieved in this non-randomised study of diabetes care might well be transferable to 36 this reduction is of the same order -a reduction in systolic blood pressure of 8.3 mmHg (95% CI = -15.6 to -3.0; P = 0.004).
Narrative observations have been made about the remaining five papers ( Table 2 ). The first group of three papers showed improvements in systolic blood pressure as a result of educational interventions by a range of clinical staff: nurse-provided intensive educational interventions in people with declining kidney function in a pre-dialysis setting;
37 the effectiveness of a pharmaceutical care model where all diabetes care management was provided by a pharmacist; 38 and the effect of highly formalised diabetes education. 39 The remaining two focused on different models for the delivery of care. 30, 31 The first compared different models for ambulatory care in hypertension, but reported on the process rather than any effects on blood pressure in people with likely CKD. 29 The final paper showed how an information system contributed to QI but made noncontemporaneous comparison of groups. 40 
DISCUSSION
Summary of main findings
There are few studies that report the effects of QI interventions in primary care for people with CKD. The small number of trials carried out in this domain were often conducted on high-risk populations including ethnic minorities, although their pooled effects appear similar. They appear to have a positive effect of lowering systolic blood pressure by around 10 mmHg.
Strengths and limitations of the study
This systematic review is the first summarising the effects of quality improvement interventions on blood pressure control in people with CKD. Although only three randomised studies were available for quantitative comparative analysis, these studies all examined interventions delivered by non-doctor healthcare professionals, and a positive effect was seen in all. The magnitude of this effect was similar to that in the observational non-randomised study also included in the quantitative analysis.
The search was limited to that provided through the Cochrane review groups, which is a potential source of bias; however, this approach may have led to more systematic inclusion of articles than if the study had run its own searches. It is also accepted that only searching for English language papers introduces language bias, but no facilities were available to translate papers. The study conclusions are limited by the small number of studies identified, and it was not possible to complete a meaningful sensitivity analysis based on study quality, as intended in the method.
It is also recognised that some case studies were included on the basis of a high likelihood of CKD rather than on the basis of eGFR readings.
Comparison with existing literature
Nurse interventions have been carried out in CKD to improve quality, but in an observational study with no comparator group rather than in any form of trial. 41 However, the reduction achieved in systolic blood pressure (9 mmHg) is similar to that achieved in the QI studies reviewed earlier in this paper.
Implications for future research and clinical practice
It appears that educational interventions run by nurses and pharmacists can be effective in lowering blood pressure in high-risk groups -although this may or may not be generalisable across the wider population. Practitioners with lists that have high rates of diabetes and vascular disease could consider implementing targeted services that actively call in and follow-up people at increased cardiovascular risk or who have diabetes. These patients should have their eGFR checked and their urine screened for proteinuria using a quantitative measure of proteinuria -ideally the albumin/creatinine ratio. Those with positive tests should have their blood pressure and cardiovascular risk controlled in line with national guidance. 15 The gap identified in the literature justifies the QI intervention trial planned, 23 but also suggests that there is additional scope to test targeted, possibly non-doctor-led, educational and therapeuticfocused interventions with higher-risk patients.
There is a place for QI in CKD. That place appears to be demonstrated for specialist team members dealing with selected high-risk populations. Further research is needed to establish the place of other broader cross-practice and locality-and technologybased QI initiatives.
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